Endocrine-related cancer · 2026
Cryoablation of bone metastases in thyroid and adrenocortical cancers.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Freitas Ricardo Miguel Costa, Hoff Ana Oliveira, Fragoso Maria Candida Barisson Villares, Sousa Angela Maria, Danilovic Debora Lucia Seguro, de Castroneves Luciana Audi, Grigio Thiago Ramos, Tsunemi Miriam Harumi, Buchpiguel Carlos Alberto, Caldas Jose Guilherme Mendes Pereira
Аннотация
ABSTRACT: The purpose of this study is to assess the feasibility, efficacy and safety of cone-beam computed tomography (CBCT)-guided cryoablation of bone metastases in thyroid and adrenocortical cancers. Adult patients with bone metastases and at least 1 skeletal-related event (pain, risk of fracture, spinal cord compression or hypercalcemia) at baseline were enrolled in a prospective, single-arm, single-center IRB-approved study (ClinicalTrials: NCT03986593). Brief Pain Inventory - Short Form (BPI-SF) and morphine-equivalent daily dose (M-EDD) were recorded at baseline and weekly during the first 8 weeks and 3, 6, 12 and 24 months post-cryoablation. Adverse events (AEs) and pre- and post-treatment cross-sectional (CT or MR) and functional imaging with PET/CT were analyzed. Seventeen patients (mean age of 58.3 ± 16.2 years old; 11 women) with either differentiated (n = 8; 47.1%) or medullary thyroid cancer (n = 6; 35.6%), or adrenocortical cancer (n = 3; 17.3%) were enrolled. CBCT-guided cryoablation of 24 bone metastases reached 100% technical success rate. An overall drop of 4.8 points (P < 0.05) in the worst pain in the last 24 h and M-EDD overall intake decrease (P < 0.05) were observed. In addition to pain improvement, no patients required surgery. Three patients (17.6%) required radiotherapy due to refractory or recurrent pain over a follow-up of 14.9 ± 14.0 (median ± IQR) months. No grade 4 or 5 AE was reported. One grade 3 AE (5.9%) and two grade 2 AEs (11.8%) occurred. PET/CT imaging showed a 52% reduction in FDG uptake immediately after cryoablation. Cryoablation of bone metastases in thyroid and adrenocortical cancers was safe and effective, providing rapid and long-lasting pain relief and improving quality of life. ClinicalTrials.gov: NCT03986593.
CLINICAL RELEVANCE STATEMENTS: Cryoablation led to a sustained reduction in pain with a mean improvement of 7.2 points on a 1-10 scale of the Brief Pain Inventory - Short Form (BPI-SF) after 54 weeks. Pain relief and quality-of-life improvement (assessed by the BPI-SF) were observed in 81.3% of bone metastases just one week after cryoablation with an overall pain score reduction of 4.8 points. Cryoablation of bone metastases from endocrine cancers was safe and effective, providing long-lasting pain relief.
CLINICAL RELEVANCE STATEMENTS: Cryoablation led to a sustained reduction in pain with a mean improvement of 7.2 points on a 1-10 scale of the Brief Pain Inventory - Short Form (BPI-SF) after 54 weeks. Pain relief and quality-of-life improvement (assessed by the BPI-SF) were observed in 81.3% of bone metastases just one week after cryoablation with an overall pain score reduction of 4.8 points. Cryoablation of bone metastases from endocrine cancers was safe and effective, providing long-lasting pain relief.